Kornimate/medical-research-clean huggingface dataset:
magnetoencephalography by optical pumping magnetometer

Conditions: Magnetoencephalography; Optical Pump Magnetometer; Neonate; Premature

Summary: magnetoencephalography (meg) is a method of recording brain activity with high temporal resolution and good spatial resolution, compared to current recording techniques such as electroencephalography (eeg). the main limitation of meg is its cost due to the sensors used, the super quantum interference devices (squid). these require a complex infrastructure from an instrumentation point of view to operate, requiring liquid helium, most often at a loss, at increasing cost. optical pumping magnetometers (opm) type sensors represent a promising alternative to squids sensors, especially since they do not require helium cooling. the purpose of this project is to identify biomarkers in magnetoencephalography of normal brain development in healthy adults, premature and term newborns from "a priori" obtained by the classical technique of high resolution eeg performed.


Eligibility criteria:
inclusion criteria: * for healthy adult volunteers * age between 18 and 65 * no pathology, no treatment * no toxicant intake * for term newborns * child between 38 and 42 weeks gestational age on the day of registration * no pathology, no treatment * for children born prematurely * child between 28 and 36 weeks gestational age on the day of registration * no pathology, no treatment apart from routine care related to prematurity * for pregnant women * pregnant with between 28 to 40 weeks gestational age on the day of registration * no pathology, no treatment exclusion criteria: * subject and patients "not compatible" meg. wearers of prosthesis or pacemaker likely to generate artefacts interfering with the measurement. there is no danger to the subject, but the measurement itself may be impossible. * patients who cannot stand to stand still for a few minutes. * newborn on ventilatory assistance or infusion * newborn baby not meeting the age criteria

Keywords: magnetoencephalography optical pump magnetometer neonate premature
enhancing recovery after cardiac surgery

Conditions: Coronary Artery Disease; Depression

Summary: patients recovering from coronary artery bypass graft (cabg) surgery have high rates of depression, and depression is associated with higher risk of complications and death. recent discoveries show that depression involves changes in certain molecules in the blood, which are also involved in progressive coronary artery disease (cad) and its complications. this study will evaluate the effects of cognitive behavioral therapy (cbt) as a treatment for depression on these biological markers among cabg patients.


Eligibility criteria:
inclusion criteria: * undergone cabg at one of our recruitment sites exclusion criteria: * less than 45 years of age * have cognitive impairment or major comorbid psychiatric conditions * have autoimmune disorder or malignancy * currently smoking
a study of abicipar pegol in patients with neovascular age-related macular degeneration

Conditions: Macular Degeneration

Summary: this is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between japanese and non-japanese.


Eligibility criteria:
inclusion criteria: * diagnosis of wet age-related macular degeneration in at least 1 eye * best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye exclusion criteria: * hypersensitivity, allergy, or anaphylactic reaction to iodine * cataract or refractive surgery within the last 3 months * history of vitrectomy
glenohumeral cortisone injection

Conditions: Humeral Fractures

Summary: the objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

this is a randomized control trial to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

Eligibility criteria:
inclusion criteria: 1.18-90 2. proximal humerus fracture 3. decreased range of motion at 6 wk follow-up 4. likely to be available for follow up for 26 wks exclusion criteria: 1. known drug allergy to kenalog or lidocaine 2. unable to complete functional outcome 3. pregnant women
enhancement of emmetropization in hyperopic infants

Conditions: Hyperopia; Hypermetropia; Farsightedness

Summary: to determine if wearing a moderate spectacle under-correction (3.00d) and performing activities designed to stimulate accurate accommodation during a 15-month period will enhance emmetropization in highly hyperopic (between +5.00d and +7.00d) 3-month old infants.

the purpose of the project is to determine if emmetropization can be enhanced in very farsighted babies. we will give them glasses with a partial correction, an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. this 'boost' is meant to enable very farsighted babies to use their eyes in a normal way and emmetropize as normal infants. this partial correction would be given at 3 months of age for a period of up to 15 months. a program of visual engagement is also provided in order to encourage the normal development and use of accommodation. as changes in farsightedness occur, the power of the glasses will be reduced at follow up appointments to keep the farsightedness within the zone of effective emmetropization. once an infant reaches a normal amount of farsightedness, the glasses would be discontinued.

Eligibility criteria:
inclusion criteria: * 3 months of age (between 8 weeks and 20 weeks)at the baseline examination * either gender, any ethnicity * birthweight greater than 2500g * normal pregnancy and delivery (including cesarean section delivery but excluding serious complications or conditions such as eclampsia or rubella) * hyperopia of +5.00d or more but less than +7.00d spherical equivalent refractive error in each eye by cycloplegic retinoscopy using cyclopentolate 1% * currently under the care of a pediatrician exclusion criteria: * anisometropia greater than 1.00d (difference in spherical equivalent) * strabismus * previous history of difficulty with pupillary dilation * history of cardiac, liver, asthma, or other respiratory disease * history of ocular disease or active ocular inflammation

Keywords: hyperopia ocular refraction infant vision
optimized rehabilitation following primary breast cancer surgery

Conditions: Rehabilitation; Breast Neoplasms; Psychological Distress

Summary: this study aims to evaluate the effects of an intervention based on systematic screening of psychological distress as the basis for individualised support and rehabilitation following primary breast cancer surgery focusing on psychological , physical and health-economics outcomes. the aim is also to illuminate patients' and relatives' experiences and need of support during the rehabilitation .

breast cancer survivors are known to suffer from remaining problems from their treatment after surgery. despite numerous of studies evaluating the effect of various rehabilitation programs it is know that patients often receive rehabilitation recommendations that are general rather than individualised to their needs. the large amount of studies within this area have contributed to knowledge about potential beneficial rehabilitation interventions for these patients but there is still a lack of knowledge about how patients specific needs of rehabilitation can be identified and how health care can adjust and individualize rehabilitation to optimize rehabilitation. this study aims to evaluate the effects of an intervention based on systematic screening of psychological distress as the basis for individualised support and rehabilitation following primary breast cancer surgery focusing on psychological , physical and health-economics outcomes. the aim is also to illuminate patients' and relatives' experiences and need of support during the rehabilitation.

Eligibility criteria:
inclusion criteria: * undergone treatment for primary breast cancer * ≤18 years old * ability to communicate in swedish * written informed consent exclusion criteria: * recurrent disease * palliative diagnosis * pregnancy * prior history of breast cancer * inability to participate in the study due to cognitive impairment
peer-supported internet mediated psychological treatment

Conditions: Psychological Phenomena and Processes; Behavior and Behavior Mechanisms; Mental Disorder; Behavioral Disciplines and Activities

Summary: this study evaluates the effect and experience of peer-support in internet mediated act (acceptance and commitment therapy) in an explorative pilot study with mixed method design conducted in primary care. peer-supporters are certified support persons with personal experience of mental health problems and the process of rehabilitation, which becomes professionally active in care and support to patients in their recovery

the study is a mixed methods design consisting of an un-controlled pragmatic effectiveness study combined with semi-structured interviews in order to investigate the participant´s experience of treatment. participants were recruited from patients who were referred to a central unit for internet- cbt (cognitive behavioral therapy) in primary care in västra götaland region, sweden. peer-supporters were recruited through a swedish patient organization. participants were adults 18 years of age or older with an anxiety disorder. all participants were interviewed by a psychologist with a diagnostic instrument, a structured interview called prime-md, before starting treatment. after the interview, all patients who were offered icbt and met the inclusion criteria were requested to participate in the study. patients who accepted inclusion were guided by both a psychologist and a peer-support in the icbt treatment used in the study. the icbt treatment program used is a transdiagnostic program aimed at treating people with mild to moderate anxiety problems. quantitative data about psychosocial symptoms were collected, and qualitative data about the participants experience of treatment were collected through semi-structured interviews.

Eligibility criteria:
inclusion criteria: * participants must have reached the age of 18 * have access to a computer with internet connection * speak and understand swedish * meet the diagnostic criteria for an anxiety disorder (social anxiety, gad, panic disorder, obsessive-compulsive disorder, or unspecified anxiety disorder). exclusion criteria: * have started medication or have made major changes regarding their medication in the past few months * have serious suicidal ideation or suicide plans * are expected to have complex problems or be in need of other care * are under any other psychological treatment during the time of the treatment period.

Keywords: icbt primary care anxiety drop-out peer-support mixed method design
electronic alert system for improving thromboprophylaxis in hospitalized medical patients

Conditions: Venous Thromboembolism

Summary: the investigators aim to investigate whether a computer-based alert system in the electronic patient chart and order entry system using the geneva risk score as clinical decision support tool to estimate the risk of venous thromboembolism improves the rate of appropriate thromboprophylaxis among hospitalized medical patients.

the use of thromboprophylaxis among acutely ill hospitalized medical patients remains inconsistent. the present study aims to improve the use of appropriate thromboprophylaxis by implementing a computer-based alert system combined with a geneva risk score calculation tool in the electronic patient chart and order entry system. consecutive acutely ill medical patients without indication for therapeutic anticoagulation or ongoing therapeutic anticoagulant treatment admitted to the medical wards of the university hospital bern, switzerland, will be randomized in a 1:1 fashion to the alert group in which an alert and the geneva risk score calculation tool will be issued in the electronic patient chart or to the control group in which no alert will be issued. the primary endpoint is the rate of appropriate thromboprophylaxis during hospital stay.

Eligibility criteria:
inclusion criteria: * acutely ill medical patients admitted to medical wards exclusion criteria: * indication for therapeutic anticoagulation or ongoing therapeutic anticoagulant treatment
to determine effect and safety of tadalafil taken by men of different races and with different diseases when needed for erections

Conditions: Impotence

Summary: to compare men of different races and those with diabetes or depression to white men that do not have diabetes or depression but also suffer from the inability to get or keep an erection.


Eligibility criteria:
inclusion criteria: * at least 3 months history of erectile dysfunction (ed) * anticipate a monogamous relationship with a female sexual partner * be able to make minimum required sexual intercourse attempts * abstain from using any other ed treatment exclusion criteria: * other primary sexual disorders * history of penile implant or clinically significant penile deformity * history or current nitrate use * history of certain heart problems * history of certain kidney problems
clinical study of mrna vaccine in patients with liver cancer after operation

Conditions: Posto Perative Hepatocellular Carcinoma

Summary: this is an open, one-arm study to evaluate the safety and efficacy of mrna personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with sintilimab injection for adjuvant prevention of postoperative recurrence of hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * are ≥18 years old (including boundary values), without limitation of sex at time of consent. * the patient was confirmed as hepatocellular carcinoma by histopathology or cytology after surgery, and the lesion was completely resected by surgery r0 (no residual tumor under postoperative microscope and naked eye), and no residual lesion or extrahepatic metastasis was confirmed by postoperative imaging (ct/mri). * the patient is at high risk of postoperative recurrence, and the tumor must meet the following characteristics: patients with hepatocellular carcinoma iib/iiia as defined by the 2019 chinese staging system. * the eastern oncology consortium physical state score (ecog ps) is 0 or 1, and the child-pugh rating is a exclusion criteria: * known allergy to any tumor vaccine, adjuvant, stintilimab injection formulation, fluorouracil inj, oxaliplatin injcalcies; * tumor mutation load (tmb) was less than 2.0/mb or neonatal antigen load (tnb) was less than 0.5/mb or the predicted number of neonatal antigens was less than 15;
a study to evaluate the efficacy, safety, and pharmacokinetics of abt-493 and abt-530 with and without ribavirin in adults with hcv who failed a prior daa containing therapy

Conditions: Chronic Hepatitis C; Hepatitis C Virus; HCV; Direct-Acting Antiviral Agent (DAA)-Experienced

Summary: the purpose of this study is to assess the efficacy and safety of abt-493 and abt-530 with or without ribavirin (rbv) in participants with chronic hepatitis c virus, (hcv)-infection who previously failed treatment with a direct acting antiviral (daa)-containing regimen.


Eligibility criteria:
inclusion criteria: 1. patients from 18 to 70 years in arms a, b, and c; patients 18 years of age or older in arms d and e. 2. previous treatment with daa-containing regimen for chronic hepatitis c virus (hcv) infection resulting in either on-treatment virologic failure or post-treatment relapse 3. chronic hcv genotype (gt) 1, 4, 5, or 6-infection (gt4-6 in arms d and e) exclusion criteria: 1. history of severe, life-threatening or other significant sensitivity to any drug 2. female who is pregnant, planning to become pregnant during the study or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study 3. recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol 4. positive for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) 5. co-infection with more than one hcv genotype

Keywords: hepatitis c hcv genotype 6 hcv gt1 interferon (ifn) free hcv genotype 5 hcv hcv gt4 hcv genotype 4 chronic hepatitis c chronic hcv hepatitis c genotype 1 hcv gt5 hcv genotype 1
overlap fgids and genetic polymorphism

Conditions: Functional Gastrointestinal Disorders; Overlap Syndromes

Summary: 1. to analyze the prevalence of overlap syndromes among nerd or rh, fd, and ibs patients, and to identify and to compare the differences in their characteristics and symptoms, and to determine their risk factors. 2. to identify the differences in clinical features according to sex and gender. 3. to analyze the effect of genetic polymorphisms on overlap fgids over long-term follow-up period.


Eligibility criteria:
inclusion criteria: fgid group * no organic diseases in routine laboratory tests, abdominal imaging, esophagogastroscopy, and colonoscopy * nerd or reflux hypersensitivity (rh): typical heartburn occurring at least once a week without visible esophageal mucosal break detected by endoscopy * fd or ibs: based on the rome iii criteria control group - subjects who underwent gi evaluations as part of health check-up or for other problems, such as mild abdominal discomfort or pain for a relatively short period of time, but had no organic problems during gi endoscopy exclusion criteria: * history of gi surgery except appendectomy * inflammatory bowel disease * any malignancy, or systemic diseases requiring chronic medication except for hypertension and diabetes mellitus * pregnant or lactating women * hepatic, biliary, or psychiatric disorders requiring medication.

Keywords: functional gastrointestinal disorder overlap syndromes functional dyspepsia irritable bowel syndrome non-erosive reflux disease reflux hypersensitivity
eureca (europeanrelapsecalprotectin) study

Conditions: Inflammatory Bowel Diseases

Summary: this study will investigate the correlation of fecal calprotectin (fc) values to quiescent ulcerative colitis and to disease activity (relapse) as assessed by clinical data and endoscopy.

the study is prospective with a longitudinal approach. about 200 patients will be followed every 3 to 12 months (at basal, 3, 6, 9 and 12 months alternating visits to telephone contacts) and subsequently for further 6 months in 3 different sites (competitive enrollment, 1site/country, italy, france and spain respectively). fecal samples for immunoassays will be collected at follow up visits, stored frozen (-20°c) and sent to testing lab for their determination. the following assessments are foreseen: clinical history and demography (screening), proctosigmoidoscopy (basal), hemochromo with wbc differential count, c-reactive protein (every 6 months from screening up to 12 months; relapse), coagulation (screening) specimen collection for fecal calprotectin determination (within 1-2 weeks from informed consent signature; for basal time point; every next 3 months from basal up to 12 months and at month 18; relapse), coproculture for salmonella, shigella, e. coli and campylobacter (relapse), pharmacological ongoing therapy, mayo score (each time point; relapse)

Eligibility criteria:
inclusion criteria: * adults,18 years and older, either genders * subject previously diagnosed with left-sided colitis or pancolitis based on endoscopy and, if available, confirmed by histological examination of biopsy taken during endoscopy * subject in clinical and endoscopic remission. remission will be documented by proctosigmoidoscopy. * subject who may receive maintenance therapy as per current medical practice, e.g. mesalazine, corticosteroids, azathioprine, anti-tnf * availability of stool specimen for basal time point * subject willing and able to sign, the approved informed consent form for this project in accordance with international and national regulations * subject able to understand and follow study procedures exclusion criteria: * any subject that does not meet the inclusion criteria * subject with microscopic colitis * subject with crohn's disease * subject with limited proctitis * subject with severe chronic disease affecting the possibility to comply with the study protocol (i.e. severe cardiovascular disease, renal or liver failure, neurologic disease, hematological disease and mental disorder) * subject who is regularly taking oral anticoagulants * subject who is currently pregnant or lactating * subject unable or unwilling to subscribe informed consent * subject unable or unwilling to perform required study procedures
growth mindset intervention for older adults with chronic disease

Conditions: Chronic Disease

Summary: this study was conducted to develop and investigate the effectiveness of a growth mindset intervention based on growth mindset theory.

the study employed a quasi-randomized controlled trial design conducted over 12 weeks. before conducting the study, the researchers numbered the wards of internal medicine departments (excluding intensive care units) according to the order of bed number. the wards were then randomly divided into intervention wards and control wards using a random number generator. patients were recruited to the control group (e-health only) in the control ward and the intervention group (growth mindset intervention+ e-health) in the intervention unit. participants in the control group could undergo the training after the study concluded.

Eligibility criteria:
inclusion criteria: * aged≥60 years * diagnosed≥1 chronic disease * owned at least one smartphone * could communicate clearly in writing or orally * were willing to participate in this study exclusion criteria: * could not use wechat or phone to communicate * diagnosed as mental illness or cognitive impairment * suffered from acute severe disease or lost self-care ability * undergoing other similar training